{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:25:59Z","timestamp":1787840759753,"version":"build-2784847793"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fonds de Recherche du Qu\u00e9bec-Sant\u00e9"},{"name":"Canadian Network on Hepatitis C"},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"crossref","award":["R01DA033679"],"award-info":[{"award-number":["R01DA033679"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"crossref","award":["R21DA047902"],"award-info":[{"award-number":["R21DA047902"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"crossref","award":["1R21DA046809"],"award-info":[{"award-number":["1R21DA046809"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Men who have sex with men who ever injected drugs (ever MSM-IDU) carry a high hepatitis C virus (HCV) burden. We estimated whether current HCV testing and treatment in San Francisco can achieve the 2030 World Health Organization (WHO) HCV elimination target on HCV incidence among ever MSM-IDU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A dynamic HCV\/HIV transmission model among MSM was calibrated to San Francisco data, including HCV antibody (15.5%, 2011) and HIV prevalence (32.8%, 2017) among ever MSM-IDU. MSM had high HCV testing (79%\u201386% ever tested, 2011\u20132019) and diagnosed MSM had high HCV treatment (65% ever treated, 2018). Following coronavirus disease 2019 (COVID-19)\u2013related lockdowns, HCV testing and treatment decreased by 59%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among all MSM, 43% of incident HCV infections in 2022 were IDU-related. Among ever MSM-IDU in 2015, HCV incidence was 1.2\/100 person-years (95% credibility interval [CrI], 0.8\u20131.6). Assuming COVID-19\u2013related declines in HCV testing\/treatment persist until 2030, HCV incidence among ever MSM-IDU will decrease by 84.9% (95% CrI, 72.3%\u201390.8%) over 2015\u20132030. This decline is largely attributed to HCV testing and treatment (75.8%; 95% CrI, 66.7%\u201389.5%). Slightly greater decreases in HCV incidence (94%\u201395%) are projected if COVID-19 disruptions recover by 2025 or 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We estimate that HCV incidence will decline by &amp;gt;80% over 2015\u20132030 among ever MSM-IDU in San Francisco, achieving the WHO target.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad169","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T14:48:33Z","timestamp":1690210113000},"page":"662-673","source":"Crossref","is-referenced-by-count":8,"title":["Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis"],"prefix":"10.1093","volume":"228","author":[{"given":"Adelina","family":"Artenie","sequence":"first","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Stone","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley N","family":"Facente","sequence":"additional","affiliation":[{"name":"School of Public Health, University of California Berkeley , Berkeley, California , USA"},{"name":"Facente Consulting , Richmond, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hecht","sequence":"additional","affiliation":[{"name":"San Francisco AIDS Foundation , San Francisco, California , USA"},{"name":"Springboard HealthLab , Berkeley, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Perry","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Facente Consulting , Richmond, California , USA"},{"name":"University of California San Francisco Alliance Health Project , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willi","family":"McFarland","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wilson","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan D","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2023091519545773300_jiad169-B1","author":"World Health Organization"},{"key":"2023091519545773300_jiad169-B2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","article-title":"Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis","volume":"6","author":"Jin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"2023091519545773300_jiad169-B3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/01.aids.0000167351.00503.92","article-title":"Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs","volume":"19","author":"Iba\u00f1ez","year":"2005","journal-title":"AIDS"},{"key":"2023091519545773300_jiad169-B4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s10461-011-9970-6","article-title":"High-risk behaviors associated with injection drug use among recently HIV-infected men who have sex with men in San Diego, CA","volume":"15","author":"Ghanem","year":"2011","journal-title":"AIDS Behav"},{"key":"2023091519545773300_jiad169-B5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/OLQ.0b013e3182716e59","article-title":"Hepatitis C infection among men who have sex with men, San Francisco, 2011","volume":"39","author":"Raymond","year":"2012","journal-title":"Sex Transm Dis"},{"key":"2023091519545773300_jiad169-B6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.drugpo.2010.06.001","article-title":"HIV Risk and the overlap of injecting drug use and high-risk sexual behaviours among men who have sex with men in Zanzibar (Unguja), Tanzania","volume":"21","author":"Johnston","year":"2010","journal-title":"Int J Drug Policy"},{"key":"2023091519545773300_jiad169-B7","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1002\/hsr2.704","article-title":"A cross-sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: implications for HIV and hepatitis C virus prevention","volume":"5","author":"Artenie","year":"2022","journal-title":"Health Sci Rep"},{"key":"2023091519545773300_jiad169-B8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2019.11.022","article-title":"High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis","volume":"72","author":"Hoornenborg","year":"2020","journal-title":"J Hepatol"},{"key":"2023091519545773300_jiad169-B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269977","article-title":"Risk factors for HCV transmission in HIV-positive men who have sex with men in M\u00e9xico","volume":"17","author":"Mata-Mar\u00edn","year":"2022","journal-title":"PLoS One"},{"key":"2023091519545773300_jiad169-B10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/cid\/cit197","article-title":"Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984\u20132011","volume":"57","author":"Witt","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights","volume":"62","author":"Martin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/gutjnl-2020-321744","article-title":"Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach","volume":"70","author":"Castry","year":"2021","journal-title":"Gut"},{"key":"2023091519545773300_jiad169-B13","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/hep.28769","article-title":"Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions","volume":"64","author":"Salazar-Vizcaya","year":"2016","journal-title":"Hepatology"},{"key":"2023091519545773300_jiad169-B14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267853","article-title":"Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: a modeling analysis","volume":"17","author":"Marquez","year":"2022","journal-title":"PLoS One"},{"key":"2023091519545773300_jiad169-B15","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25059","article-title":"Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour","volume":"21","author":"Scott","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2023091519545773300_jiad169-B16","article-title":"Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis","volume":"19","author":"Macgregor","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2023091519545773300_jiad169-B17","author":"End Hep C SF"},{"key":"2023091519545773300_jiad169-B18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/QAI.0b013e318285febf","article-title":"A new trend in the HIV epidemic among men who have sex with men, San Francisco, 2004\u20132011","volume":"62","author":"Raymond","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023091519545773300_jiad169-B19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/OLQ.0b013e3181f68ed4","article-title":"Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008","volume":"38","author":"Raymond","year":"2011","journal-title":"Sex Transm Dis"},{"key":"2023091519545773300_jiad169-B20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10461-018-2299-7","article-title":"Increases in pre-exposure prophylaxis use and decreases in condom use: behavioral patterns among HIV-negative San Francisco men who have sex with men, 2004\u20132017","volume":"23","author":"Chen","year":"2019","journal-title":"AIDS Behav"},{"key":"2023091519545773300_jiad169-B21","article-title":"Estimated hepatitis C prevalence and key population sizes in San Francisco: a foundation for elimination","volume":"13","author":"Facente","year":"2018","journal-title":"PLoS One"},{"key":"2023091519545773300_jiad169-B22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s10461-018-2321-0","article-title":"Estimated population size of men who have sex with men, San Francisco, 2017","volume":"23","author":"Raymond","year":"2019","journal-title":"AIDS Behav"},{"key":"2023091519545773300_jiad169-B23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/00333549221083741","article-title":"Hepatitis C elimination during a global pandemic: a case study of resilience in action","volume":"137","author":"Facente","year":"2022","journal-title":"Public Health Rep"},{"key":"2023091519545773300_jiad169-B24","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1093\/cid\/ciac175","article-title":"Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States","volume":"75","author":"Hoenigl","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B25","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"2023091519545773300_jiad169-B26","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1001\/jama.2019.2591","article-title":"Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force","volume":"321","author":"Chou","year":"2019","journal-title":"JAMA"},{"key":"2023091519545773300_jiad169-B27","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2023091519545773300_jiad169-B28","author":"HIV.org"},{"key":"2023091519545773300_jiad169-B29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciu447","article-title":"Vertical transmission of hepatitis C virus: systematic review and meta-analysis","volume":"59","author":"Benova","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"2023091519545773300_jiad169-B31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12879-016-1807-5","article-title":"Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis","volume":"16","author":"Smith","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2023091519545773300_jiad169-B32","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1007\/s10620-010-1147-z","article-title":"Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US","volume":"55","author":"Cheung","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2023091519545773300_jiad169-B33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: aASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"key":"2023091519545773300_jiad169-B35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2036.2008.03657.x","article-title":"Effectiveness of pegylated interferon\/ribavirin combination in \u2018real world\u2019 patients with chronic hepatitis C virus infection","volume":"27","author":"Borroni","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2023091519545773300_jiad169-B36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055373","article-title":"Treatment outcomes of treatment-na\u00efve hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts","volume":"8","author":"Davies","year":"2013","journal-title":"PLoS One"},{"key":"2023091519545773300_jiad169-B37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1574887114666190306154650","article-title":"Real-World efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection","volume":"14","author":"Scotto","year":"2019","journal-title":"Rev Recent Clin Trials"},{"key":"2023091519545773300_jiad169-B38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cgh.2019.05.047","article-title":"Gaps in viral hepatitis awareness in the United States in a population-based study","volume":"18","author":"Zhou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023091519545773300_jiad169-B39","author":"Centers for Disease Control and Prevention"},{"key":"2023091519545773300_jiad169-B40","author":"Centers for Disease Control and Prevention"},{"key":"2023091519545773300_jiad169-B41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1471-2334-14-217","article-title":"Differences in outpatient care and treatment utilization for patients with HIV\/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study","volume":"14","author":"Johnson","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2023091519545773300_jiad169-B42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jval.2017.12.025","article-title":"Effect of interferon-free regimens on disparities in hepatitis C treatment of US veterans","volume":"21","author":"Barnett","year":"2018","journal-title":"Value Health"},{"key":"2023091519545773300_jiad169-B43","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1093\/cid\/ciac038","article-title":"Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States\u2014a time series analysis","volume":"75","author":"Huang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023091519545773300_jiad169-B44","author":"EndHepC SF"},{"key":"2023091519545773300_jiad169-B45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2023091519545773300_jiad169-B46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ije\/dyt243","article-title":"Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis","volume":"43","author":"Aspinall","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2023091519545773300_jiad169-B47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2468-1253(21)00311-3","article-title":"Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO","volume":"7","author":"Artenie","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023091519545773300_jiad169-B48","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1080\/00918369.2020.1804258","article-title":"\u201cSlam sex\u201d \u2014sexualized injecting drug use (\u201cSIDU\u201d) amongst men who have sex with men (MSM)\u2014a scoping review","volume":"68","author":"Scheibein","year":"2021","journal-title":"J Homosex"},{"key":"2023091519545773300_jiad169-B49","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1478-3231.2010.02305.x","article-title":"Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany","volume":"30","author":"Vogel","year":"2010","journal-title":"Liver Int"},{"key":"2023091519545773300_jiad169-B50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/cid\/ciaa021","article-title":"Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom?","volume":"72","author":"Garvey","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad169\/50947621\/jiad169.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/6\/662\/51608192\/jiad169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/6\/662\/51608192\/jiad169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T19:55:47Z","timestamp":1694807747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/6\/662\/7230026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,7,24]]},"published-print":{"date-parts":[[2023,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad169","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,7,24]]}}}